GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 195.75

Change

-9.05 (-4.42)%

Market Cap

USD 12.78B

Volume

49.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-15 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

+0.12 (+0.24%)

USD 477.58B
MATA:F Panasonic Corporation

-0.01 (-5.88%)

USD 20.38B
1CK:F CK Asset Holdings Limited

+0.11 (+3.12%)

USD 13.66B
0PY:F Paycom Soft

-4.60 (-2.16%)

USD 12.23B
2U4:F HICL Infrastructure PLC

+0.01 (+0.70%)

USD 2.74B
CLN:F The City of London Investment ..

+0.04 (+0.70%)

USD 2.00B
JR0:F Just Group plc

-0.02 (-1.20%)

USD 1.76B
R7I:F RENEWABLES INFRASTRUCTURE

-0.02 (-1.96%)

USD 1.63B
CE2:F CropEnergies AG

N/A

USD 1.00B
31X:F NB PRIVATE EQUITY PART.A

-0.30 (-1.60%)

USD 0.89B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.89% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.89% N/A N/A 21% F
Trailing 12 Months  
Capital Gain -34.64% N/A N/A 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.64% N/A N/A 18% F
Trailing 5 Years  
Capital Gain -2.42% N/A N/A 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.42% N/A N/A 44% F
Average Annual (5 Year Horizon)  
Capital Gain 4.60% N/A N/A 55% F
Dividend Return 4.60% N/A N/A 49% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.52% N/A N/A 48% F
Risk Adjusted Return 16.72% N/A N/A 46% F
Market Capitalization 12.78B N/A N/A 88% B+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike